<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03449225</url>
  </required_header>
  <id_info>
    <org_study_id>115217B3E</org_study_id>
    <nct_id>NCT03449225</nct_id>
  </id_info>
  <brief_title>Prenatal Computer-Aided Genetics Education Module</brief_title>
  <acronym>CAGEM</acronym>
  <official_title>Development of a Computer-Aided Genetics Education Module (CAGEM) on Screening and Testing for Fetal Chromosome Conditions and Carrier Status: A Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A standard part of obstetrical care is offering prenatal genetic screening. Numerous&#xD;
      professional guidelines have emphasized the importance of pretest counseling for prenatal&#xD;
      genetic screenings. Informed consent includes the optional nature of the test, information on&#xD;
      the conditions being screened, possible test results, implication of each result, and the&#xD;
      type of test offered (screening or diagnostic). This responsibility falls on the physician in&#xD;
      a busy clinic. Technology may be able to address this limitation and give consistent pretest&#xD;
      counseling for patients waiting for their appointment. This study is looking to evaluate the&#xD;
      use of computer-aided genetics education module for facilitating decision making about&#xD;
      prenatal genetic screening and testing for fetal chromosome conditions and carrier status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale Cytogenetic abnormalities are present in nearly 1% of live births, in approximately&#xD;
      2% of pregnancies in women older than 35 years who undergo prenatal diagnosis, and in fully&#xD;
      half of all spontaneous, first-trimester abortions. Genetic counseling and screening for&#xD;
      cytogenetic abnormalities are an integral part of routine obstetrical care. There are various&#xD;
      screening options and strategy available commercially, including screening for the fetus and&#xD;
      parental carrier screening. Currently American College of Obstetrics and Gynecology (ACOG)&#xD;
      recommends that all pregnant women should be offered screening for fetal aneuploidy. ACOG&#xD;
      also recommends panethnic screening for cystic fibrosis, hemoglobinopathies and spinal&#xD;
      muscular atrophy carrier status. For other conditions, glycogen storage diseases and fragile&#xD;
      X syndrome, the recommendation currently is to screen based on ethnicity and family history.&#xD;
      Without thorough counseling, pregnant women may accept multiple screenings without&#xD;
      considering the downstream consequences, including anxiety created by additional, sometimes&#xD;
      uncertain, information.&#xD;
&#xD;
      Numerous professional societies guidelines have emphasized the importance of pre-test&#xD;
      counseling in this setting due to the delicate and complicated nature of genetic conditions.&#xD;
      Along with these guidelines, typically minimal recommended information to be provided during&#xD;
      a pre-test counseling was included. Generally it involves, the optional nature of the test,&#xD;
      general information about condition tested, nature of testing (screening, carrier screening&#xD;
      or diagnostic), testing options, possible testing result, implication of each result, cost&#xD;
      and availability of genetic counseling should needed. The responsibility of offering these&#xD;
      tests and to perform pre-test counseling lie primarily on the obstetrical care providers and&#xD;
      has become more burdensome as the number of testing options expands and also due to limited&#xD;
      time for discussion during a prenatal care.&#xD;
&#xD;
      Technology may be able to address these limitations. Various studies have evaluated the use&#xD;
      of Computerized Decision Aids (CDAs) in facilitating high-quality decision making in various&#xD;
      health related contexts with promising results (17-20). CDAs are generally superior to&#xD;
      traditional decision aids such as, paper-based or video-based, due to the possibility to&#xD;
      tailor CDAs based on the information provided, the ease of information dissemination and also&#xD;
      their interactive features which reinforce participation. This study is looking to evaluate&#xD;
      the use of computer-based pre-test education for prenatal cytogenetic abnormalities&#xD;
      screening.&#xD;
&#xD;
      Statement of Problem Per professional society guidelines, all women should be offered&#xD;
      prenatal screening and/or diagnostic testing for fetal aneuploidy (chromosome conditions such&#xD;
      as Down syndrome, trisomy 18, trisomy 13, and sex chromosome abnormalities) during pregnancy.&#xD;
      Women should also be offered population-based carrier screening but have the option of&#xD;
      expanded carrier screening as well. There are an increasing number of testing and screening&#xD;
      options available during pregnancy. The obstetrics provider is primarily responsible for&#xD;
      ensuring patients are informed about their options and the benefits, risks, and limits of&#xD;
      each. These discussions can be time intensive in a setting where the time available is often&#xD;
      limited. As such, there is a need to find alternate ways to educate women about their&#xD;
      prenatal testing and screening options.&#xD;
&#xD;
      Objectives The overarching purpose of the full project is to determine whether a computer&#xD;
      aided genetics education module can improve pregnant women's knowledge about their options&#xD;
      for fetal aneuploidy (chromosome) screening and testing and carrier screening and facilitate&#xD;
      informed decision making.&#xD;
&#xD;
      The specific aims of the current study are to:&#xD;
&#xD;
        -  To develop a computer-aided genetics education module for prenatal cytogenetic&#xD;
           abnormalities screening and testing and carrier screening&#xD;
&#xD;
        -  To determine the acceptability of the computer-aided genetics educational module for&#xD;
           women presenting for care in an obstetrics clinic&#xD;
&#xD;
        -  To determine the feasibility of using the computer-aided genetics educational module in&#xD;
           a busy obstetrics clinic&#xD;
&#xD;
        -  To assess whether use of the module increases knowledge and enhances informed decision&#xD;
           making&#xD;
&#xD;
        -  To compare the effectiveness of the computer-aided education module to standard care in&#xD;
           terms of knowledge gained and impact on decision making&#xD;
&#xD;
      This study will be done in two phases. Phase 1 will involve evaluating the acceptability of&#xD;
      the computer-aided genetics education module. Changes will be made to the module based on the&#xD;
      feedback obtained. The revised module will then be used for Phase 2. Phase 2 will involve&#xD;
      comparing the effectiveness of the computer-aided genetics education module to standard care.&#xD;
&#xD;
      Methodology&#xD;
&#xD;
      A clinician who has access to the daily clinic patient list will identify patients eligible&#xD;
      to participate in the study and notify an onsite study team member. Eligible study&#xD;
      participants will then be approached by one of the study team members (either a genetic&#xD;
      counselor, a genetic counseling student, a medical student, or a maternal-fetal medicine&#xD;
      fellow) and be invited to participate in the study. The potential participant will be given&#xD;
      the study information sheet and the study team member will review it with her. If the&#xD;
      approached participant agrees to take part, participant will be randomized into one of the&#xD;
      two arms of the study-control versus tests arm. Randomization will be performed using&#xD;
      Qualtrics platform.&#xD;
&#xD;
        -  Control arm: The participant will be given a digital device (IPad or Kindle Fire) to&#xD;
           complete a pre-education survey (web-based pre-intervention survey housed on the&#xD;
           Qualtrics platform). Once the survey is complete, the participant will proceed with&#xD;
           standard education, provided by a resident/physician in the clinic, about prenatal&#xD;
           screening and testing for chromosome conditions and for carrier status. Once the&#xD;
           standard education has been completed, the participant will be approached to complete a&#xD;
           post-education survey which includes questions about knowledge, intent to have or&#xD;
           decline screening or testing, and demographic variables. Once the post-education survey&#xD;
           is completed, the participant will be given a $5 gift card for her time. Participation&#xD;
           in the study is then complete.&#xD;
&#xD;
        -  Test arm: The participant she will be given a digital device on which to access the&#xD;
           computer-aided genetics educational module. Prior to accessing the module, the&#xD;
           participant will be asked to complete a pre-education survey (web-based pre-intervention&#xD;
           survey housed on the Qualtrics platform). Once she has completed the survey, she will&#xD;
           interact with the module which is tailored for her clinical situation. Once the&#xD;
           participant has completed reviewing the module, she will be asked to complete the&#xD;
           web-based post-module survey which includes questions about knowledge, intent to have or&#xD;
           decline screening or testing, acceptability of the module, and demographic variables.&#xD;
&#xD;
        -  All responses (control and test) will be recorded using a unique participant&#xD;
           identification number in order to pair pre- and post-intervention responses. The&#xD;
           identifier will not be linked to any identifiable information. Of note, all subjects&#xD;
           will receive standard provider counseling after completion of the study module (standard&#xD;
           of care).&#xD;
&#xD;
      Phase 1: During Phase 1, The investigators will assess the acceptability of the&#xD;
      computer-aided genetics educational module in our target study population. During this&#xD;
      initial phase, The investigators will only be doing the test arm of the study. Quantitative&#xD;
      and qualitative responses from the pre- and post-surveys will be obtained from batches of 10&#xD;
      samples; the module will then be optimized based on the qualitative feedback and overall&#xD;
      results on the knowledge, acceptability, and informed consent questions. This will be&#xD;
      repeated until user acceptability reaches 80% of the maximum score.&#xD;
&#xD;
      The computerized educational module has been developed based on counseling points recommended&#xD;
      by the American College of Obstetrics and Gynecology and is based on a previous study&#xD;
      investigating computer-aided education. The application can be accessed at&#xD;
      https://interva-online.mobi/CAGEM/participant/guestLogin.do?packageId=178&#xD;
&#xD;
      Survey Instruments There are three separate survey instruments, all of which have been&#xD;
      developed on the Qualtrics survey platform. The pre-education survey instrument is the same&#xD;
      for control and test participants and includes basic knowledge questions about genetic&#xD;
      testing and screening for chromosome conditions and carrier status. The questions are based&#xD;
      on the standard information that should be presented when providing genetic counseling on&#xD;
      these topics.&#xD;
&#xD;
      There are two versions of the post-intervention survey. Both versions include knowledge&#xD;
      questions (same as pre-test questions) and demographic questions. The surveys differ in that&#xD;
      the survey for those taking part in the test arm include questions about the acceptability of&#xD;
      the computer-aided genetics educational module.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 7, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Knowledge of Genetics</measure>
    <time_frame>Participant will be assessed from the time of randomization and again after clinical encounter (and intervention, for the study arm). The total estimated time will be approximately 1 hour since randomization.</time_frame>
    <description>Survey will be used to assess subjects' knowledge on prenatal genetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Testing Intention</measure>
    <time_frame>Participant will be assessed from the time of randomization and again after clinical encounter (and intervention, for the study arm). The total estimated time will be approximately 1 hour since randomization.</time_frame>
    <description>Survey will be used to assess subjects' intention to accept or decline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Software Acceptability</measure>
    <time_frame>Participant will be assessed from the time after the completion of intervention material usage. This is a one time survey, total estimated time is approximately 10 minutes.</time_frame>
    <description>Survey will be used to assess the software acceptability among subjects</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Autosomal Recessive Disorder</condition>
  <condition>Aneuploidy</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The participant will be given a digital device (IPad or Kindle Fire) to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once the survey is complete, the participant will proceed with standard education, provided by a resident/physician in the clinic, about prenatal screening and testing for chromosome conditions and for carrier status. Once the standard education has been completed, the participant will be approached to complete a post-education survey which includes questions about knowledge, intent to have or decline screening or testing, and demographic variables.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>â€¢ The participant she will be given a digital device on which to access the computer aided genetics educational module. Prior to accessing the module, the patient will be asked to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once she has completed the survey, she will interact with the Computer-Aided Genetic Education Module which is tailored for her clinical situation. Once the participant has completed reviewing the module, she will be asked to complete the web-based post-module survey which includes questions about knowledge, intent to have or decline screening or testing, acceptability of the module, and demographic variables.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Computer-Aided Genetic Education Module</intervention_name>
    <description>Subjects will be provided with an electronic device to view Computer-Aided Genetic Education Module (CAGEM) software. This is an interactive software designed to provide subjects with tailored information regarding prenatal screening options for carrier status and aneuploidy.</description>
    <arm_group_label>Test Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant with gestational age of less than 24 weeks&#xD;
&#xD;
          -  Good understanding of spoken English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of genetic disorder&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manesha Putra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manesha Putra, MD</last_name>
    <phone>7732419231</phone>
    <email>manesha.putra@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hutzel Women's Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manesha Putra, MD</last_name>
      <phone>773-241-9231</phone>
      <email>manesha.putra@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>April 30, 2019</last_update_submitted>
  <last_update_submitted_qc>April 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Manesha Putra, MD</investigator_full_name>
    <investigator_title>Obstetrics and Gynecology Resident Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneuploidy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

